Tumor-suppressive microRNA-452 inhibits migration and invasion of breast cancer cells by directly targeting RAB11A

Li,Wanjun; Li,Guoyin; Fan,Zhigang; Liu,Tao

doi:10.3892/ol.2017.6426

Tumor-suppressive microRNA-452 inhibits migration and invasion of breast cancer cells by directly targeting RAB11A

Authors:
- Wanjun Li
- Guoyin Li
- Zhigang Fan
- Tao Liu
View Affiliations

Affiliations: Department of Pathology, Affiliated 3201 Hospital of Xi'an Jiaotong University, Hanzhong, Shaanxi 723000, P.R. China, Department of Medical Oncology, Affiliated 3201 Hospital of Xi'an Jiaotong University, Hanzhong, Shaanxi 723000, P.R. China
Published online on: June 20, 2017 https://doi.org/10.3892/ol.2017.6426
Pages: 2559-2565

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is the most common type of malignant tumor in females, and metastasis is the most common cause of breast cancer-associated mortality. Previous studies have identified that abnormal expression of microRNAs is commonly observed in human cancer and may be crucial for cancer metastasis. In the present study, microRNA‑452 (miR‑452) was investigated for its ability to act as a tumor suppressor in breast cancer. miR‑452 expression was quantified in breast cancer tissue samples and cell lines with reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). Transwell migration and invasion assays were used to investigate the effect of miR‑452 on the migration and invasion capabilities of breast cancer cells. Potential target genes of miR‑452 were identified with miRanda and TargetScan. A luciferase reporter assay was performed to validate RAB11A as a putative target of miR‑452, and was corroborated by RT‑qPCR and western blot analyses. Finally, small interfering RNA (siRNA) was used to knockdown RAB11A expression and confirm whether miR‑452 inhibited breast cancer cell migration and invasion via the negative regulation of RAB11A. The results revealed that miR‑452 was downregulated in breast cancer tissues and cell lines, and that its downregulation may be associated with breast cancer metastasis, as miR‑452 expression inhibited the migration and invasion capacities of breast cancer cells. RT‑qPCR and western blot analyses indicated that miR‑452 negatively regulated the expression of RAB11A mRNA and protein. The luciferase reporter assay revealed that miR‑452 specifically bound to the 3'‑untranslated region of RAB11A. Furthermore, inhibition of RAB11A with siRNA inhibited breast cancer cell migration and invasion. In conclusion, the present study has demonstrated that miR‑452 may act as a tumor suppressor gene via inhibition of cell migration and invasion by targeting RAB11A in breast cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
3	Xue J, Chen Z, Gu X, Zhang Y and Zhang W: MicroRNA-148a inhibits migration of breast cancer cells by targeting MMP-13. Tumour Biol. 37:1581–1590. 2016. View Article : Google Scholar : PubMed/NCBI
4	Sharma S, Kelly TK and Jones PA: Epigenetics in cancer. Carcinogenesis. 31:27–36. 2010. View Article : Google Scholar : PubMed/NCBI
5	Beckmann MW, Niederacher D, Schnurch HG, Gusterson BA and Bender HG: Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med (Berl). 75:429–439. 1997. View Article : Google Scholar : PubMed/NCBI
6	Gradishar WJ: Treatment of metastatic breast cancer. J Natl Compr Canc Netw. 12 5 Suppl:S759–S761. 2014. View Article : Google Scholar
7	Martin HL, Smith L and Tomlinson DC: Multidrug-resistant breast cancer: Current perspectives. Breast Cancer (Dove Med Press). 6:1–13. 2014.PubMed/NCBI
8	Takahashi RU, Miyazaki H and Ochiya T: The roles of MicroRNAs in breast cancer. Cancers (Basel). 7:598–616. 2015. View Article : Google Scholar : PubMed/NCBI
9	Gamucci T, D'Ottavio AM, Magnolfi E, Barduagni M, Vaccaro A, Sperduti I, Moscetti L, Belli F and Meliffi L: Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer. Br J Cancer. 97:1040–1045. 2007. View Article : Google Scholar : PubMed/NCBI
10	Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
11	Wan L, Pantel K and Kang Y: Tumor metastasis: Moving new biological insights into the clinic. Nat Med. 19:1450–1464. 2013. View Article : Google Scholar : PubMed/NCBI
12	Wang Z and Ouyang G: Periostin: A bridge between cancer stem cells and their metastatic niche. Cell Stem Cell. 10:111–112. 2012. View Article : Google Scholar : PubMed/NCBI
13	Teng G and Papavasiliou FN: Shhh! Silencing by microRNA-155. Philos Trans R Soc Lond B Biol Sci. 364:631–637. 2009. View Article : Google Scholar : PubMed/NCBI
14	Hydbring P and Badalian-Very G: Clinical applications of microRNAs. F1000Res. 2:1362013.PubMed/NCBI
15	Gromak N: Intronic microRNAs: A crossroad in gene regulation. Biochem Soc Trans. 40:759–761. 2012. View Article : Google Scholar : PubMed/NCBI
16	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
17	Hwang HW and Mendell JT: MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 96 Suppl:R40–R44. 2007.PubMed/NCBI
18	Ryan BM, Robles AI and Harris CC: Genetic variation in microRNA networks: The implications for cancer research. Nat Rev Cancer. 10:389–402. 2010. View Article : Google Scholar : PubMed/NCBI
19	Shukla GC, Singh J and Barik S: MicroRNAs: Processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol. 3:83–92. 2011.PubMed/NCBI
20	Wu D, Zhou Y, Pan H, Zhou J, Fan Y and Qu P: microRNA-99a inhibiting cell proliferation, migration and invasion by targeting fibroblast growth factor receptor 3 in bladder cancer. Oncol Lett. 7:1219–1224. 2014.PubMed/NCBI
21	Wu D, Pan H, Zhou Y, Zhang Z, Qu P, Zhou J and Wang W: Upregulation of microRNA-204 inhibits cell proliferation, migration and invasion in human renal cell carcinoma cells by downregulating SOX4. Mol Med Rep. 12:7059–7064. 2015.PubMed/NCBI
22	Wang CZ, Yuan P and Li Y: MiR-126 regulated breast cancer cell invasion by targeting ADAM9. Int J Clin Exp Pathol. 8:6547–6553. 2015.PubMed/NCBI
23	van Schooneveld E, Wildiers H, Vergote I, Vermeulen PB, Dirix LY and Van Laere SJ: Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res. 17:212015. View Article : Google Scholar : PubMed/NCBI
24	He Z, Xia Y, Pan C, Ma T, Liu B, Wang J, Chen L and Chen Y: Up-Regulation of MiR-452 inhibits metastasis of non-small cell lung cancer by regulating BMI1. Cell Physiol Biochem. 37:387–398. 2015. View Article : Google Scholar : PubMed/NCBI
25	Kristensen H, Haldrup C, Strand S, Mundbjerg K, Mortensen MM, Thorsen K, Ostenfeld MS, Wild PJ, Arsov C, Goering W, et al: Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. Clin Cancer Res. 20:2169–2181. 2014. View Article : Google Scholar : PubMed/NCBI
26	Liu L, Chen K, Wu J, Shi L, Hu B, Cheng S, Li M and Song L: Downregulation of miR-452 promotes stem-like traits and tumorigenicity of gliomas. Clin Cancer Res. 19:3429–3438. 2013. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Wei C, Luo Q, Sun X, Li D, Song H, Li X, Song J, Hua K and Fang L: MicroRNA-497 induces cell apoptosis by negatively regulating Bcl-2 protein expression at the posttranscriptional level in human breast cancer. Int J Clin Exp Pathol. 8:7729–7739. 2015.PubMed/NCBI
29	Hong W and Dong E: The past, present and future of breast cancer research in China. Cancer Lett. 351:1–5. 2014. View Article : Google Scholar : PubMed/NCBI
30	Bockhorn J, Prat A, Chang YF, Liu X, Huang S, Shang M, Nwachukwu C, Gomez-Vega MJ, Harrell JC, Olopade OI, et al: Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models. Cancer Res. 74:7406–7417. 2014. View Article : Google Scholar : PubMed/NCBI
31	Erturk E, Cecener G, Polatkan V, Gokgoz S, Egeli U, Tunca B, Tezcan G, Demirdogen E, Ak S and Tasdelen I: Evaluation of genetic variations in miRNA-binding sites of BRCA1 and BRCA2 genes as risk factors for the development of early-onset and/or familial breast cancer. Asian Pac J Cancer Prev. 15:8319–8324. 2014. View Article : Google Scholar : PubMed/NCBI
32	Sun EH, Zhou Q, Liu KS, Wei W, Wang CM, Liu XF, Lu C and Ma DY: Screening miRNAs related to different subtypes of breast cancer with miRNAs microarray. Eur Rev Med Pharmacol Sci. 18:2783–2788. 2014.PubMed/NCBI
33	Cai ZK, Chen Q, Chen YB, Gu M, Zheng DC, Zhou J and Wang Z: microRNA-155 promotes the proliferation of prostate cancer cells by targeting annexin 7. Mol Med Rep. 11:533–538. 2015.PubMed/NCBI
34	Zheng Q, Sheng Q, Jiang C, Shu J, Chen J, Nie Z, Lv Z and Zhang Y: MicroRNA-452 promotes tumorigenesis in hepatocellular carcinoma by targeting cyclin-dependent kinase inhibitor 1B. Mol Cell Biochem. 389:187–195. 2014. View Article : Google Scholar : PubMed/NCBI
35	Hu Q, Gong JP, Li J, Zhong SL, Chen WX, Zhang JY, Ma TF, Ji H, Lv MM, Zhao JH and Tang JH: Down-regulation of miRNA-452 is associated with adriamycin-resistance in breast cancer cells. Asian Pac J Cancer Prev. 15:5137–5142. 2014. View Article : Google Scholar : PubMed/NCBI
36	Bhuin T and Roy JK: Rab11 in disease progression. Int J Mol Cell Med. 4:1–8. 2015.PubMed/NCBI
37	Mosesson Y, Mills GB and Yarden Y: Derailed endocytosis: An emerging feature of cancer. Nat Rev Cancer. 8:835–850. 2008. View Article : Google Scholar : PubMed/NCBI
38	Gelsi-Boyer V, Orsetti B, Cervera N, Finetti P, Sircoulomb F, Rougé C, Lasorsa L, Letessier A, Ginestier C, Monville F, et al: Comprehensive profiling of 8p11-12 amplification in breast cancer. Mol Cancer Res. 3:655–667. 2005. View Article : Google Scholar : PubMed/NCBI
39	Caswell PT, Chan M, Lindsay AJ, McCaffrey MW, Boettiger D and Norman JC: Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments. J Cell Biol. 183:143–155. 2008. View Article : Google Scholar : PubMed/NCBI
40	Zhang J, Liu X, Datta A, Govindarajan K, Tam WL, Han J, George J, Wong C, Ramnarayanan K, Phua TY, et al: RCP is a human breast cancer-promoting gene with Ras-activating function. J Clin Invest. 119:2171–2183. 2009.PubMed/NCBI
41	Wang B, Yang Z, Wang H, Cao Z, Zhao Y, Gong C, Ma L, Wang X, Hu X and Chen S: MicroRNA-320a inhibits proliferation and invasion of breast cancer cells by targeting RAB11A. Am J Cancer Res. 5:2719–2729. 2015. View Article : Google Scholar : PubMed/NCBI